FAM
BCAB icon

Fred Alger Management’s BioAtla BCAB Stock Holding History

Fred Alger Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-701
Closed -$289K – 525
2022
Q4 		$289K Sell
701
-122
-15% -$50.6K ﹤0.01% 424
2022
Q3 		$317K Buy
+823
New +$269K ﹤0.01% 414

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fred Alger Management's BCAB Position: Q1 2023 in Review

Fred Alger Management sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 701 shares — an estimated $289K sold.

Fred Alger Management first reported a position in BCAB in Q3 2022 and held it in 2 quarters. The position peaked at $317K in Q3 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

  • Fred Alger Management reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
  • Fred Alger Management sold 701 BioAtla shares in Q1 2023, an estimated $289K.
  • Fred Alger Management first reported a position in BioAtla in Q3 2022 and held it in 2 quarters.
  • Fred Alger Management's BioAtla position peaked at $317K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on Fred Alger Management's 13F filing for Q1 2023, filed 15 May 2023.